Cynata Therapeutics Limited (CYYNF) fair value: what the stock is really worth
As of Oct 30, 2026: fair value (intrinsic value) of Cynata Therapeutics Limited stock $0.01, price $0.01, upside +0.4%, quality 44 out of 100. Rating: fairly valued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.
- Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free
Cynata Therapeutics Limited
CYYNF · USThe stock is already about fairly priced and weak company.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.
How to read this chart
60‑month range $0.0014 – $0.4000 · fair‑value band $0.0071 – $0.0074 · the $0.0072 price screens below the $0.0072 fair value. As of Nov 10, 2026.
Every Wednesday you see whether Cynata Therapeutics is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Company profile
Cynata Therapeutics Limited, together with its subsidiaries, engages in the development and commercialization of proprietary induced pluripotent stem cell and mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia.
Show moreShow less
The company's lead therapeutic product candidate is CYP-001, which has completed Phase 2 clinical trial for the treatment of graft versus host disease.
It is also involved in the development of CYP-004, which is in Phase 3 clinical trial used for the treatment of osteoarthritis; CYP-006TK, a novel polymercoated silicon wound dressing for diabetic wounds; and Diabetic Foot Ulcer which has completed phase 1 trial for the treatment of non-healing wounds on the feet/lower limbs.
Further, it develops Cohort 1 which has completed Phase 1/2 for the treatment of kidney transplant. Cynata Therapeutics Limited has a license arrangement with Fujifilm corporation. The company was formerly known as Eco Quest Limited and changed its name to Cynata Therapeutics Limited in October 2013.
Cynata Therapeutics Limited was incorporated in 2003 and is based in Cremorne, Australia.
Stock analysis
Cynata Therapeutics Limited (CYYNF) currently trades at $0.0072, while our estimate is $0.0072, so the stock looks roughly fairly valued today (gap 0.4%).
Show more
Valuation
None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.
Scenario range: $0.0071 (bear) to $0.0074 (bull), the price of $0.0072 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 44/100 (below-average quality), in the Healthcare sector.
Weak Growth: Growth has flattened: the last year, three and five years all grew more slowly than the long-term average.
Cynata Therapeutics Limited reported revenue of A$1.7M in FY2026 versus A$7.8M in FY2022, a compound −31.5%/yr. Reported net income was −A$9.1M in FY2026.
Key figures
Market cap $1.7M Micro · P/S ratio 1.02 · EPS (TTM) $−0.0200 · Return on equity −341% · Return on assets (EBIT) −168% (5-year average) · Operating margin −466% · Revenue (TTM) A$1.7M · Revenue growth (YoY) −10.0%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 12 out of 100 (low confidence).
What moves the price
The share trades about 97% below its 52-week high and 414% above its 52-week low.
For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at 0%, CYYNF screens cheaper than that median.
Fair Value
Quality Score breakdown
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Revenue & earnings trend
Watch CYYNF, get fair value alerts →
Compare Cynata Therapeutics Limited with another stock
Price, fair value, quality and upside side by side.
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 847 stocks
Valuation Multiplesvs Biotechnology median · lower = cheaper
Strength profile in five axes (Snowflake)
PAST 0: with negative equity (buybacks among others) return on equity is not meaningfully computable.
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- EV/EBITDA by industry
- Dividend yield by industry
- Stock screener with 62 metrics
- Undervalued stocks: US Stocks
- Valuation of the USA market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value | Compare |
|---|---|---|---|---|
| Regeneron Pharmaceuticals, Inc REGN | $952.40 | $1,275 | +34% | vs CYYNF |
| Vertex Pharmaceuticals Incorporated VRTX | $537.79 | $592.46 | +10% | vs CYYNF |
| Samsung Biologics Co 207940 | 1,423,000 KRW | 1,552,100 KRW | +9% | vs CYYNF |
| argenx SE ARGX | $950.95 | $908.40 | −4% | vs CYYNF |
| CSL Limited CSL | A$199.55 | A$186.49 | −7% | vs CYYNF |
| Moderna, Inc MRNA | $215.27 | $135.64 | −37% | vs CYYNF |
| BeOne Medicines AG 6160 | HK$249.40 | HK$152.92 | −39% | vs CYYNF |
| Revolution Medicines, Inc RVMD | $166.87 | $88.78 | −47% | vs CYYNF |
| Celltrion, Inc 068270 | 214,500 KRW | 74,945 KRW | −65% | vs CYYNF |
| Royalty Pharma plc RPRX | $68.53 | $19.01 | −72% | vs CYYNF |
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Cynata Therapeutics Limited (CYYNF) overvalued or undervalued?
What is the fair value of CYYNF?
What is the quality score of CYYNF?
What is the price target for Cynata Therapeutics Limited (CYYNF)?
What is the Cynata Therapeutics Limited stock forecast for 2026?
What is the revenue of Cynata Therapeutics Limited (CYYNF)?
What is the intrinsic value of Cynata Therapeutics Limited (CYYNF)?
Is Cynata Therapeutics Limited stock overvalued or undervalued in 2026?
Is fair value the same as the market price of CYYNF?
How much is Cynata Therapeutics Limited worth?
What do the bullish and bearish scenarios say about CYYNF?
How solid is the balance sheet of Cynata Therapeutics Limited (CYYNF)?
How far is CYYNF from its 52-week high?
Which stocks are comparable to Cynata Therapeutics Limited?
Is Cynata Therapeutics Limited stock attractive at the current price?
Is it still worth investing in stocks now?
What is the share price of Cynata Therapeutics Limited (CYYNF)?
What should I pay attention to with Cynata Therapeutics Limited right now?
Key figures of Cynata Therapeutics Limited
How large is the market capitalisation of Cynata Therapeutics Limited (CYYNF)?
What is the P/S ratio of Cynata Therapeutics Limited (CYYNF)?
What are the earnings per share of Cynata Therapeutics Limited (CYYNF)?
What is the return on equity of Cynata Therapeutics Limited (CYYNF)?
What is the EBIT return on assets of Cynata Therapeutics Limited (CYYNF)?
What is the operating margin of Cynata Therapeutics Limited (CYYNF)?
How fast is revenue growing at Cynata Therapeutics Limited (CYYNF)?
How much free cash flow does Cynata Therapeutics Limited (CYYNF) generate?
How much net cash does Cynata Therapeutics Limited (CYYNF) hold?
Watch Cynata Therapeutics Limited in the live analysis
One click puts Cynata Therapeutics Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.